Maxim Group Reiterates Sell on Momenta (MNTA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
December 21, 2015 8:01 AM ESTCAMBRIDGE, Mass., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that it has resumed patient enrollment in its ongoing Phase 2 portion of the trial A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination with nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer. Study enrollment was paused last month following Momentas acceptance of recommendations from its Data Safety Monitoring Board (DSMB) to develop guidelines for diagnosing and managing thrombocytopenia, based on a limited number of specific toxicities observed in the study.
... MoreBaxalta and Momenta Announce M923, a Proposed HUMIRA (adalimumab) Biosimilar, Met Primary Endpoint in Pharmacokinetic Study
December 21, 2015 6:45 AM ESTBANNOCKBURN, Ill. and CAMBRIDGE, Mass., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Baxalta Incorporated (NYSE: BXLT) and Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), today announced that M923 met the primary endpoint in a randomized, double-blind, three-arm, parallel group, single-dose study. The primary objective of the study was to evaluate the pharmacokinetics of M923 compared to both U.S. and EU sourced HUMIRA® reference products.
... More